MCD outcomes after rituximab-based therapy, based on the treatment
| Treatment with Rituximab . | Total at baseline . | Initial response . | Disease progression . | MCD relapse . | Kaposi sarcoma . | Lymphoma . | Death . |
|---|---|---|---|---|---|---|---|
| All | 99 | 95 | 36 | 25 | 4 | 3 | 4 |
| HIV+ | 73 | 70 | 24 | 15 | 4 | 1 | 4 |
| HIV– | 26 | 25 | 12 | 10 | 0 | 2 | 0 |
| Rituximab alone | 17 | 17 | 10 | 8 | 0 | 0 | 2 |
| Rituximab + etoposide | 71 | 68 | 24 | 17 | 3 | 2 | 2 |
| Rituximab + other chemotherapy | 11 | 10 | 2 | 0 | 1 | 1 | 0 |
| Treatment with Rituximab . | Total at baseline . | Initial response . | Disease progression . | MCD relapse . | Kaposi sarcoma . | Lymphoma . | Death . |
|---|---|---|---|---|---|---|---|
| All | 99 | 95 | 36 | 25 | 4 | 3 | 4 |
| HIV+ | 73 | 70 | 24 | 15 | 4 | 1 | 4 |
| HIV– | 26 | 25 | 12 | 10 | 0 | 2 | 0 |
| Rituximab alone | 17 | 17 | 10 | 8 | 0 | 0 | 2 |
| Rituximab + etoposide | 71 | 68 | 24 | 17 | 3 | 2 | 2 |
| Rituximab + other chemotherapy | 11 | 10 | 2 | 0 | 1 | 1 | 0 |